Tox in Ten

In this episode Dr. Gillian Beauchamp sits down with Dr. David Jiang to discuss new research into mitochondrial involvement in organophosphate toxicity and strategies to fill the gaps in traditional supportive care for cholinergic crisis. 

In this episode Dr. Gillian Beauchamp sits down with Dr. Alan Woolf to discuss the "toxicologic tetrad " and the "two hit" model and how they relate to development of pediatric cancer. 

In this episode Dr. Gillian Beauchamp sits down with Dr. Stephanie Weiss to discuss research examining GLP-1 receptor agonists in the treatment of Alcohol Use Disorder.

In this episode Dr. Gillian Beauchamp sits down with Donna Papsun to discuss the nuance of forensic laboratory testing of Kratom products, especially with the development of synthetic Kratom alkaloids. 

In this episode Dr. Gillian Beauchamp sits down with Dr. Patil Armenian to discuss how US federal law may hinder harm reduction efforts at mass gatherings/festivals and how toxicologists can get involved. 

In this episode Dr. Gillian Beauchamp sits down with Dr. Cait Bonney to discuss MDMA. 

ACMT Highlights Episode 70 - Festival Drugs  In this episode Dr. Gillian Beauchamp sits down with Dr. Benjamin Hatten to discuss drug use during festivals including self report of substances used versus what is found on surveillance testing. 

In this episode Dr. Gillian Beauchamp sits down with Dr. Tim Erickson to discuss CBRNE and mass casualty training in Ukraine. 

In this episode Dr. Gillian Beauchamp sits down with Dr. Robert "Cole" Pueringer to discuss 3 key features of fentanyl which lead to high opioid tolerance. This high opioid tolerance can lead to more severe withdrawal syndromes and difficulty with initiating buprenorphine or methadone.  Rapid inpatient methadone initiation may be more effective than outpatient initiation.

In this episode Dr. Gillian Beauchamp sits down with Dr. Benjamin Hatten to discuss the potential role of psychedelics in palliative care medicine. Specifically data that shows improved outcomes in individuals who experience psychological stress related to a terminal or life limiting illness that is refractory to more traditional treatments such as antidepressants